New drugs such as Cibinqo Tab (Pfizer Korea), a treatment for atopic dermatitis, and Newmaco S, a treatment for high triglycerides, which were listed in July, were included in the list of cost-effective, high-dose oral drugs. If multiple prescriptions are made for low content, the cost of claiming benefits can be reduced by exceeding the upper limit for high-content products.

Cibinqo Tab, a treatment for atopic dermatitis in adolescents and adults that inhibits JAK1, was listed as reimbursement through NHIS negotiations on July 1. As for the JAK1 inhibitor, it is the second drug to be covered after AbbVie's Rinvoq ER 15mg for the treatment of atopic dermatitis in adolescents aged 12 years and older. Thr